AIC468

About AiCuris

AiCuris is a clinical-stage biotech company developing targeted antiviral therapies, with a lead asset, pritelivir, demonstrating positive Phase 3 results for refractory herpes simplex virus (HSV) in immunocompromised patients. The company has built a robust pipeline targeting significant unmet needs in severe infectious diseases and is led by an experienced management team with deep virology and commercial expertise. In February 2026, the company entered into an agreement to be acquired by Asahi Kasei, which is expected to accelerate its growth and global reach.

Therapeutic Areas